Six abstracts accepted for presentation includes post hoc analyses and real-world evidence for ZYMFENTRA® (infliximab-dyyb) Findings reinforce clinical decision-making in long-term management of ...

An increased risk of both invasive and superficial fungal infections was observed among patients who received TNF-α inhibitors for various conditions.